Production (Stage)
Elite Pharmaceuticals, Inc.
ELTP
$0.517
-$0.0022-0.42%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.00M | -10.89M | -11.04M | 615.80K | 3.33M |
| Total Depreciation and Amortization | 520.50K | 489.60K | 553.50K | 558.70K | 500.80K |
| Total Amortization of Deferred Charges | 3.50K | 3.50K | 3.50K | 3.50K | -- |
| Total Other Non-Cash Items | -4.22M | 11.91M | 14.20M | 2.91M | -4.01M |
| Change in Net Operating Assets | -9.38M | -2.58M | -2.26M | -942.50K | 2.28M |
| Cash from Operations | 3.92M | -1.06M | 1.46M | 3.14M | 2.10M |
| Capital Expenditure | -754.10K | 0.00 | -92.40K | -778.50K | -403.60K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 110.00K | 15.30K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | -900.00K | -- |
| Cash from Investing | -754.10K | 0.00 | 17.60K | -1.66M | -403.60K |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -156.30K | -193.10K | -320.70K | -174.90K | -401.00K |
| Issuance of Common Stock | 19.30K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -137.00K | -193.10K | -320.70K | -174.90K | -401.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.03M | -1.26M | 1.15M | 1.31M | 1.29M |